Pomerantz Law Firm Investigates Allegations Against Novartis AG for Securities Fraud

The Pomerantz Law Firm has initiated a thorough investigation on behalf of investors in Novartis AG, a notable player in the global pharmaceuticals market, traded under the ticker symbol NVS on the NYSE. The inquiry centers on allegations of securities fraud and potentially unlawful business practices by the company's officers and directors.

On September 8, 2026, Novartis released findings from its Phase III clinical trial known as the HARBOR study, which evaluated
del-desiran, a treatment aimed at individuals suffering from myotonic dystrophy type 1 (DM1). Unfortunately, the results indicated that the treatment did not exhibit a statistically significant improvement in the primary endpoint of video hand opening time, a critical measure for assessing hand myotonia. This disappointing outcome triggered a sharp decline in Novartis's stock price, with the American Depositary Share (ADS) plummeting by $22.29, or nearly 14%, closing at $137.70 on the same day.

The Pomerantz Law Firm is extending an invitation to affected investors to come forward. Those who have lost money as a result of this decline or have concerns about the integrity of the company's management are urged to reach out to Danielle Peyton via email at [email protected] or by telephone at 646-581-9980, extension 7980. This outreach aims to ensure that investors have an opportunity to participate in potential legal actions, including class action suits that may arise in response to these allegations.

Founded by the renowned Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has a longstanding reputation in the realms of corporate, securities, and antitrust class litigation. For over 85 years, Pomerantz has dedicated itself to representing victims of securities fraud and corporate misconduct. The firm's distinguished track record includes the recovery of numerous multimillion-dollar damages awards for its clients.

Given the gravity of the situation, investors are reminded that prior performances in similar circumstances do not guarantee similar outcomes, emphasizing the need for a thorough investigation into Novartis’s actions. With an ongoing commitment to protecting the rights of shareholders, Pomerantz is prepared to navigate the complex landscape of securities litigation to ensure that justice is served.

For further updates and to join the efforts in this investigating, interested parties can visit Pomerantz's official website at www.pomlaw.com.

The implications of this investigation are significant, not only for Novartis and its management but also for the broader investment community. Investors rely on accurate information and ethical behavior from companies in which they invest. Any misstep, whether through negligence or intentional misconduct, can have far-reaching impacts on both shareholder value and public trust in the corporate sector.

As this situation unfolds, all eyes will be on Novartis, Pomerantz LLP, and the affected investors, navigating this challenging moment in the pharmaceutical industry. Stakeholders should stay informed and be proactive in protecting their interests.